Zai Lab Ltd. Unsponsored ADR Stock

$32.43

1.34% yesterday

Nasdaq, Apr 28, 10:05 pm CET

ISIN

US98887Q1040

Symbol

ZLAB

Reports

Quarter | Annual

Index

NASDAQ Composite

Sector

Health

Industry

Biotechnology

Overview Dividends Analysts Charts News Strategies

Zai Lab Ltd. Unsponsored ADR Stock price

$32.43

-31.18 49.02% 5Y

Nasdaq, Closing price Mon, Apr 28 2025

+0.43 1.34%

ISIN

US98887Q1040

Symbol

ZLAB

Reports

Quarter | Annual

Index

NASDAQ Composite

Sector

Health

Industry

Biotechnology

Key metrics

Market capitalization	$3.56b
Enterprise Value	$2.84b
P/E (TTM) P/E ratio	negative
EV/FCF (TTM) EV/FCF	negative
EV/Sales (TTM) EV/Sales	7.11
P/S ratio (TTM) P/S ratio	8.93
P/B ratio (TTM) P/B ratio	4.16
Revenue growth (TTM) Revenue growth	49.59%
Revenue (TTM) Revenue	$398.99m
EBIT (operating result TTM) EBIT	$-282.12m
Free Cash Flow (TTM) Free Cash Flow	$-221.23m
Cash position	$879.67m
EPS (TTM) EPS	$-2.60
P/E forward	negative
P/S forward	6.29
EV/Sales forward	5.01
Short interest	8.05%

As a Free StocksGuide user, you can view scores for all 6,789 stocks worldwide.

Get Started for Free Today

Zai Lab Ltd. Unsponsored ADR Stock Analysis

Unlock Scores for Free

??

17 Analysts have issued a Zai Lab Ltd. Unsponsored ADR forecast:

15x Buy

88%

More details on Analyst Estimates Including Price Targets

17 Analysts have issued a Zai Lab Ltd. Unsponsored ADR forecast:

Buy

88%

Hold

12%

Analyst Estimates with Stock Price Targets

Financial data from Zai Lab Ltd. Unsponsored ADR

Income Statement P&L | Balance Sheet | Cash Flow

Quarter TTM Annually

Dec '24		+/- %
Revenue	399 399	50% 50% 100%
- Direct Costs	148 148	54% 54% 37%
Gross Profit	251 251	47% 47% 63%
- Selling and Administrative Expenses	278 278	6% 6% 70%
- Research and Development Expense	235 235	12% 12% 59%
EBITDA	-262 -262	27% 27% -66%
- Depreciation and Amortization	20 20	14% 14% 5%
EBIT (Operating Income) EBIT	-282 -282	25% 25% -71%
Net Profit	-257 -257	23% 23% -64%

In millions USD.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Subscribe Now

Zai Lab Ltd. Unsponsored ADR Stock News

Neutral

Business Wire

●

4 days ago

Zai Lab Presents Data Highlighting Potential of Internally Developed, Next-Generation Oncology Therapies at AACR 2025

SHANGHAI & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) will present new data from studies evaluating two of its internally developed, next-generation, investigational oncology therapies that it has global rights to, ZL-6201, a novel leucine-rich repeat-containing protein 15 (LRRC15) antibody-drug conjugate (ADC) targeting multiple solid tumors, and ZL-1222, an ...

Neutral

Business Wire

●

6 days ago

Zai Lab to Present Data from Phase 1 Trial of DLL3-Targeted Antibody-Drug Conjugate (ADC) ZL-1310 at 2025 ASCO Annual Meeting

SHANGHAI & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today announced that updated data from an ongoing, global Phase 1a/1b clinical trial (NCT06179069) evaluating ZL-1310, the Company's potential first-in-class and best-in-class, Delta-like ligand (DLL3) antibody-drug conjugate (ADC) for the treatment of extensive-stage small cell lung cancer (ES-SCLC), will ...

Neutral

Business Wire

●

8 days ago

Zai Lab Announces Acceptance of Supplemental New Drug Application for Repotrectinib for Patients with NTRK-Positive Solid Tumors

SHANGHAI & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today announced that China's National Medical Products Administration (NMPA) has accepted the supplemental New Drug Application (sNDA) for repotrectinib for the treatment of adult patients with solid tumors that harbor a neurotrophic tyrosine receptor kinase (NTRK) gene fusion. The application is intended f...

More Zai Lab Ltd. Unsponsored ADR News

Company Profile

Zai Lab Ltd. is a biopharmaceutical company, which engages in the licensing, developing, and commercializing proprietary therapeutics that address areas of unmet medical need. Its product pipelines include ZL-2306, ZL-2401, FPA144, ETX2514, and ZL-2301. The company was founded by Samantha Ying Du and Marietta Wu in 2014 and is headquartered in Shanghai, China.

Head office	Cayman Islands
CEO	Ying Du
Employees	1,869
Founded	2014
Website	www.zailaboratory.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

Start now